Monoclonal antibodies to treat COVID-19 in rheumatoid arthritis: A case report and a clinical appraisal of selected drug trials
The current report describes successful treatment of a rapidly progressive severe breakthrough COVID-19 in a female physician, a known case of rheumatoid arthritis (RA). She received monoclonal antibody (Mab) combination cocktail (Casirivimab™ plus Imdevimab™) infusion on day 4 after the onset of sy...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2022-01-01
|
| Series: | Indian Journal of Rheumatology |
| Subjects: | |
| Online Access: | http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2022;volume=17;issue=3;spage=300;epage=305;aulast=Chopra |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841561347268018176 |
|---|---|
| author | Arvind Chopra |
| author_facet | Arvind Chopra |
| author_sort | Arvind Chopra |
| collection | DOAJ |
| description | The current report describes successful treatment of a rapidly progressive severe breakthrough COVID-19 in a female physician, a known case of rheumatoid arthritis (RA). She received monoclonal antibody (Mab) combination cocktail (Casirivimab™ plus Imdevimab™) infusion on day 4 after the onset of symptoms. RA was in prolonged remission with tofacitinib. She had completed vaccination 6 weeks earlier and worked in a COVID hospital. Post infusion, there was substantial improvement, and she was discharged after 3 days. However, she required intermittent domiciliary oxygen for a fortnight. Fatigue and ageusia persisted for 5 weeks. Several Mabs were recently approved for emergency use in mild-to-moderate ambulant COVID-19 patients. Controlled drug trials confirmed excellent efficacy and safety. Selected data on clinical relevance and limitations are currently described. RA is susceptible to COVID-19, and some vaccines may be less effective. Intervention with Mabs ought to be judicious and timely. |
| format | Article |
| id | doaj-art-90ff0d9eb80346f09e24640457f72fd5 |
| institution | Kabale University |
| issn | 0973-3698 0973-3701 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Indian Journal of Rheumatology |
| spelling | doaj-art-90ff0d9eb80346f09e24640457f72fd52025-01-03T01:45:34ZengSAGE PublishingIndian Journal of Rheumatology0973-36980973-37012022-01-0117330030510.4103/injr.injr_5_22Monoclonal antibodies to treat COVID-19 in rheumatoid arthritis: A case report and a clinical appraisal of selected drug trialsArvind ChopraThe current report describes successful treatment of a rapidly progressive severe breakthrough COVID-19 in a female physician, a known case of rheumatoid arthritis (RA). She received monoclonal antibody (Mab) combination cocktail (Casirivimab™ plus Imdevimab™) infusion on day 4 after the onset of symptoms. RA was in prolonged remission with tofacitinib. She had completed vaccination 6 weeks earlier and worked in a COVID hospital. Post infusion, there was substantial improvement, and she was discharged after 3 days. However, she required intermittent domiciliary oxygen for a fortnight. Fatigue and ageusia persisted for 5 weeks. Several Mabs were recently approved for emergency use in mild-to-moderate ambulant COVID-19 patients. Controlled drug trials confirmed excellent efficacy and safety. Selected data on clinical relevance and limitations are currently described. RA is susceptible to COVID-19, and some vaccines may be less effective. Intervention with Mabs ought to be judicious and timely.http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2022;volume=17;issue=3;spage=300;epage=305;aulast=Choprabreakthrough infectionscovid-19monoclonal antibodiesrheumatoid arthritisvaccination |
| spellingShingle | Arvind Chopra Monoclonal antibodies to treat COVID-19 in rheumatoid arthritis: A case report and a clinical appraisal of selected drug trials Indian Journal of Rheumatology breakthrough infections covid-19 monoclonal antibodies rheumatoid arthritis vaccination |
| title | Monoclonal antibodies to treat COVID-19 in rheumatoid arthritis: A case report and a clinical appraisal of selected drug trials |
| title_full | Monoclonal antibodies to treat COVID-19 in rheumatoid arthritis: A case report and a clinical appraisal of selected drug trials |
| title_fullStr | Monoclonal antibodies to treat COVID-19 in rheumatoid arthritis: A case report and a clinical appraisal of selected drug trials |
| title_full_unstemmed | Monoclonal antibodies to treat COVID-19 in rheumatoid arthritis: A case report and a clinical appraisal of selected drug trials |
| title_short | Monoclonal antibodies to treat COVID-19 in rheumatoid arthritis: A case report and a clinical appraisal of selected drug trials |
| title_sort | monoclonal antibodies to treat covid 19 in rheumatoid arthritis a case report and a clinical appraisal of selected drug trials |
| topic | breakthrough infections covid-19 monoclonal antibodies rheumatoid arthritis vaccination |
| url | http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2022;volume=17;issue=3;spage=300;epage=305;aulast=Chopra |
| work_keys_str_mv | AT arvindchopra monoclonalantibodiestotreatcovid19inrheumatoidarthritisacasereportandaclinicalappraisalofselecteddrugtrials |